Market Overview

Clovis Shares Reiterated As A Sell Following 10% Rally

Share:
Related CLVS
75 Biggest Movers From Yesterday
60 Stocks Moving In Tuesday's Mid-Day Session

AstraZeneca plc (ADR) (NYSE: AZN) on Tuesday presented positive Lynparza results in ovarian cancer maintenance. This raises competitive risks for Clovis Oncology Inc’s (NASDAQ: CLVS) Rubraca, which is currently in the phase III ARIEL3 maintenance study, Chardan Capital Markets’ Madhu Kumar said in a report.

Madhu reiterated a Sell rating for Clovis, with a price target of $36.

Increased Competition

Clovis is expected to present top-line results from Rubraca’s phase III ARIEL3 maintenance study in mid-2017.

“While we understand that success for a second PARPi in the setting of ovarian cancer maintenance therapy arguably further de-risks PARPi as a class in the indication, this de-risking needs to be balanced by the competitive pressures generated by multiple effective PARPis in the ovarian cancer space,” Madhu wrote.

Related Link: Wall Street's M&A Chatter From March 10-12

Moreover, positive results for competitors in the second-line maintenance setting exerts pressure on Rubraca's approved indication of third line or later therapy. The analyst added that the positive SOLO-2 result presented by AstraZeneca “raises the possible risk” of ARIEL3 failing in an absolute or relative sense.

Although Rubraca is being tested for another major indication, that of metastatic castrate-resistant prostate cancer, there are several PARPi competitors in development in combination with AR [androgen receptor] inhibitors, Madhu noted.

Latest Ratings for CLVS

DateFirmActionFromTo
Oct 2018BarclaysMaintainsOverweightOverweight
Oct 2018JP MorganDowngradesOverweightNeutral
Sep 2018Leerink SwannInitiates Coverage OnMarket Perform

View More Analyst Ratings for CLVS
View the Latest Analyst Ratings

Posted-In: Chardan Capital Markets Madhu Kumar RubracaAnalyst Color Short Ideas Reiteration Analyst Ratings Trading Ideas

 

Related Articles (AZN + CLVS)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
ACBIKeefe Bruyette & WoodsUpgrades21.0
COTYBMO CapitalUpgrades12.0
ECCOppenheimerDowngrades0.0
VYGRRaymond JamesUpgrades0.0
ATNXJP MorganUpgrades15.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

20 Stocks Moving In Wednesday's Pre-Market Session

Wedbush Cuts TESARO Target By 18% Following SOLO-2 Results